Company / Cash & Equivalents
HERBALIFE LTD. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$353.1M
FY2025
5-year range
$353.1M / $601.5M
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
#61 of 148
Health Care
What the data says
At $353M, HERBALIFE LTD.'s cash & equivalents ranks #61 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $353M in FY2025 to $1.3B in FY2017.
Based on SEC 10-K filings.
$353M in FY2025 with a 5-year CAGR of -19.5%.
Declined from $575M to $353M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.4%
- 5-Year CAGR
- -19.5%
- 10-Year CAGR
- -
Sector benchmark
#61 of 148 in Health CareTop 41% of 148This company $353.1M Sector average $1.2B
▼
-70.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -19.5%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 15.0% year-over-year.
- Ranks #61 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $353.1M | -15.0% |
| FY2024 | $415.3M | -27.8% |
| FY2023 | $575.2M | +13.2% |
| FY2022 | $508.0M | -15.5% |
| FY2021 | $601.5M | -42.5% |
| FY2020 | $1.0B | +24.5% |
| FY2019 | $839.4M | -30.0% |
| FY2018 | $1.2B | -6.2% |
| FY2017 | $1.3B | +98.1% |
| FY2016 | $645.4M | -33.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026